Neonatal vaccine effectiveness and the role of adjuvants

Isaac G. Sakala, Katherine Marie Eichinger, and Nikolai Petrovsky

A review was performed using keywords including neonatal immunity, vaccine, adjuvant, influenza, and RSV. The review addresses the issues of how to improve neonatal vaccines, which we have defined as vaccines given in the first 4 weeks of life in a human infant or the first week of life in a mouse. A search was performed using keywords including ‘neonatal immunity’, ‘neonatal immunisation’, ‘vaccine’ and ‘adjuvant’ of PubMed articles published between 1960 and 2018.

**1. Pediatric respiratory virus disease burden**

According to the World Health Organization (WHO), 2.8–3.3 million deaths annually occur in the first 4 weeks of neonatal life [1]. Fifty-two percent of the 6.3 million children who died under 5 years of age in 2013, died of infectious causes, with viruses, bacteria, and parasites all contributing to infant morbidity and mortality [2]. Influenza and respiratory syncytial virus (RSV) are common causes of acute lower respiratory infections (ALRI) in children. Influenza having an annual global attack rate of 20–30% in children (versus 5–10% in adults) [3]. Children aged <5 years have greater rates of hospitalization and complications, particularly in the presence of co-existing illnesses [4–8]. In a cohort of 209 US infants monitored weekly from birth to 1 year of age, 33% developed influenza infection [8]. In a retrospective cohort study of children hospitalized with community-acquired influenza during four consecutive influenza seasons (July 2000 through June 2004), 25% were <6 months old and 77% were children <5 years old [6]. In 2008 alone, an estimated 28,000 to 111,500 children died worldwide as a result of influenza-associated ALRI [9]. Annual global burden of RSV-associated ALRI is estimated at 33 million cases resulting in >3 million hospitalizations and ~60,000 deaths in those under 5 years of age, with RSV in children under the 1 year of age accounting for 9 times more deaths than influenza [10]. Around 80% of children have developed RSV-specific antibodies by 18 months of age and by 3 years virtually all children have been exposed [11].

**2. The neonatal immune system**

The newborn immune system has traditionally been viewed as immature [12,13] with Medawar and colleagues proposing the immaturity of the newborn immune system functioned as a barrier to autoimmunity [14]. Although mature αβ T and B cells can be detected in the fetal liver from 8 weeks of gestation [15], the newborn immune system exhibits a reduced response to active immunization with neonates responding to immunization with qualitatively and quantitatively lower memory immune responses [16]. It has more recently been suggested that reduced neonatal immunity is not a defective state of immaturity, but rather reflects necessary adaptation of the immune system to the demands placed on it in early life [15]. Regardless, the problem remains that vaccination during the neonatal period results in lower antibody and T cell responses compared to adults, resulting in reduced ability to use vaccines to prevent neonatal morbidity and mortality from infections.

**3. Potential role of adjuvants in enhancing neonatal vaccine responses**

Successful neonatal vaccines will require development of strategies to overcome these reduced adaptive immune responses in infancy. Traditional inflammatory adjuvants, improve adult vaccine responses, but are less successful in neonates [17,18]. Adjuvants act in a variety of ways to increase recruitment of immune cells to the site of injection, enhance migration of activated APCs to the draining lymph node, increase uptake of the Ag by APCs, increase APC antigen presentation and co-stimulation, all resulting in enhanced adaptive immune responses (reviewed in [19–21]). In adults, this manifests in a higher frequency of CD4+ T helper cells, and
higher antibody (Ab) titers. A key question is whether such benefits of adjuvants can be utilized to create more effective neonatal vaccines. This review explores the problems of neonatal immunization and identifies potential adjuvant solutions, focussing on new findings in respect of unique benefits of sugar-based adjuvant compounds.

4. Factors underlying reduced neonatal vaccine responses

Low and/or delayed responses to many vaccines are seen in neonatal animal models [12,22,23] reflecting what is seen in human newborns. Neonates have reduced vaccine responses because of differences in both innate and adaptive immune pathways when are compared to adults [16,24,25]. Furthermore, passively acquired maternal Abs which help protect neonates against early-life infections, may also contribute to inhibition of neonatal vaccine responses by antigen interference [26–28]. The features of the neonatal immune system are illustrated in Figure 1 [13,16,27]. The immune system in early-life is skewed towards immune tolerance because of the need to avoid autoimmunity and inflammatory immunopathology. This is reflected in increased activity of suppressive T regulatory cells [29,30], reduced antigen-presenting cell (APC) function, a higher threshold for B cell activation, reduced production of immune effectors such as inflammatory cytokines, and a bias to a T helper type 2 (Th2) phenotype [31].

APCs, including dendritic cells (DC), macrophages and monocytes, express a range of receptors/molecules that respond to pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). There are four major classes of such receptors which includes the toll-like receptors (TLRs), nod-like receptors (NLRs), retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) and C-type lectin receptors (CLRs). Activation of these receptors results in innate immune stimulation and increased pro-inflammatory cytokine production and upregulation of co-stimulatory molecules (CD40, CD80, CD86, MHC-II) facilitating increased Ag presentation to memory T and B cells. In neonates, APCs express low basal levels of co-stimulatory molecules and MHC-II, and have a decreased ability to produce cytokines, particularly interleukin-12 (IL-12), in response to TLR stimulation [16,32,33]. The downstream effect is reduced activation and expansion of memory T and B cells. While inflammatory adjuvants based on PAMPs and DAMPs enhance APC function and are effective in adults [21], these are on the whole poorly effective if at all in neonates. This suggests that the development of effective neonatal adjuvants will require a fresh approach and cannot simply rely on repurposing adjuvants shown to work in adults.

Follicular DCs (FDCs) play an essential role in B cell responses as they capture/retain Ag in the form of immune complexes for extended periods and thereby draw together Ag-specific B and T cells [34–36]. FDCs develop slowly after birth, resulting in delayed germinal center (GC) formation and ability to produce high affinity Ab [37]. Abs currently define the correlate of protection for the majority of successful vaccines against infectious agents [38]. Even if vaccines induce Ab responses in neonates, the induced Ab are quantitatively lower and qualitatively inferior compared with older individuals [13]. Lower neonatal Ab responses reflect limitations of both GC and extrafollicular plasma cell responses. Low APC Ag expression combined with low expression of costimulatory molecules causes reduced B cell receptor (BCR) signaling and hence less Ab avidity maturation and isotype switching [16,39]. In neonates, there is slow maturation of marginal zone neonatal B cells, a subset of PAMP-responsive B cells that mount rapid T-independent extra follicular B cell responses [23]. Extrinsic factors that influence the magnitude, persistence, or quality of maternal vaccine responses also include maternally derived Abs [27,40] and an increased frequency of CD4+ Foxp3+ regulatory T cells (Treg) [29,41]. Maternal Abs reduce neonatal vaccine responses
through masking neutralizing Ab epitopes, binding to the Fcy-receptor 2B, disposing of antigen and neutralizing attenuated vaccine vectors [26,27]. Tregs are present at higher levels at birth and administration of BCG or HBV vaccines to mice together with anti-CD25 Ab treatment to deplete Treg resulted in higher vaccine responses [42,43]. In human infants, malaria infection was associated with increased malaria-specific Tregs [44] and this correlated with decreased responses to BCG vaccination persisting to 1 year of age [45]. Hence, adjuvants that reduced Tregs could be beneficial for neonatal vaccines. A problem is that traditional PAMP-based adjuvants such as TLR agonists typically stimulate Tregs and anti-inflammatory cytokines such as IL-10 in neonates thereby hindering rather than helping neonatal vaccine responses [46].

CD4+ and CD8+ αβ T lymphocytes are the main adaptive immune cells responsible for B-cell help and cytotoxic killing of infected cells, respectively. During responses to vaccination or acute infection, Ag-specific CD4 + T cells proliferate and differentiate into different Th subsets: e.g., Th1, Th2, Th17, T follicular helper (TFH) cells, which are characterized by different cytokine profiles that mediate their functions. Diminished T cell responses predispose neonates to infections by intracellular pathogens. Impaired T-cell function in early life is attributed to a low T cell precursor frequency plus reduced quantity and quality of APCs [16,47]. The dominant anti-inflammatory cytokine milieu preferentially supports development of Th2 rather than Th1 responses. Moreover, as shown in mice the expression of the IL4Ra/IL13Ra heteromeric receptors by neonatal Th1 cells renders them susceptible to apoptosis upon IL-4 binding [48]. Nevertheless, the reduced Th1 capacity in neonates is not absolute because they can develop Th1 responses to some infections and vaccines, e.g., BCG [49,50], pertussis [51] and cytomegalovirus infections [52].

Memory T-cell subtypes are critical to vaccination, as they affect the type and quality of B-cell responses. In mice, Th1 cytokines induce class switching to IgG2 and IgA [53], whereas Th2-type cytokines primarily induce IgM, IgG1, IgA and IgE antibodies [54]. TFH cells are essential for the generation of high-affinity memory B cells through the GC reaction producing IL-21 plus IFN-γ or IL-4, inducing IgG2a/c and IgG1 Ab production, respectively [55–58]. Also, TFH cells play an important role in promoting IgA production, and homing of IgA-committed B cells to mucosal sites. TFH cells in tonsils and Peyer’s patches produce IL-21 that synergizes with transforming growth factor β1 (TGF-β1) to skew isotype switching toward IgA [59,60]. IL-21 also downregulates CXCR5, the chemokine receptor that promotes follicular localization of B cells and upregulates CCR10, the chemokine receptor that facilitates the migration of IgA class-switched B cells to local mucosal effector sites [61,62]. Limited neonatal GC B cell and plasma cell responses have been correlated with delayed maturation of FDCs and reduced expansion of TFH cells [63,64]. As TFH cells likely limit humoral responses to vaccines in early life [64], adjuvants that support neonatal TFH cell differentiation could be beneficial in improving neonatal vaccine responses.

5. Lessons from successful neonatal vaccines

Given the difficulties of neonatal vaccination, much could be learned from the few vaccines that have proved successful in the neonatal period [25,65–67]. BCG and HBV vaccines are routinely administered to neonates as part of the Expanded Program of Immunization (EPI) schedule. Gaining insight into how these vaccines induce neonatal protection may help in development of strategies to induce protective neonatal responses to other vaccines. BCG is a live attenuated Mycobacterium bovis vaccine administered as a single dose within the first few days of life in developing countries to prevent tuberculous meningitis and disseminated TB in children. BCG contains inherent adjuvant activity, expressing factors that stimulate PAMP receptors including TLR-2, TLR-4 and TLR-9, NOD2 and MINCLE [68,69]. The effectiveness of BCG has been linked to its ability to induce a strong neonatal Th1 immune response due to activation of all these PAMP receptors [49,50,70]. This indicates that the right immune signals can induce favorable adaptive immune responses in early life. Nevertheless, poor BCG efficacy in regions closer to the equator has been associated with prior Treg induction by environmental mycobacteria [71], highlighting the challenges even for a successful neonatal vaccine-like BCG.

HBV vaccine formulated with aluminum salt adjuvants (hydroxide or phosphate), is the other immunization administered at birth to reduce the risk of mother-to-infant transmission of HBV [70,72–74]. Children routinely receive three doses of HBV vaccine as part of childhood immunization schedules with the first dose administered within 24 h of birth and the second and third dose administered at 1–2 months and 6 – 18th months of age, respectively. This strategy is highly effective in preventing acute and chronic HBV infection in infants born to mothers who are HBV positive [75]. Notably, the dynamics of preventing infection at the time of birth by a birth dose of HBV vaccine is different to the use of birth doses of vaccine to protect against prospective infections such as influenza or RSV, where short duration low-level immunity induced by a birth dose may not be sufficient to protect for more than a few weeks after vaccine administration, if at all.

WHO also recommends an oral polio vaccine (OPV) dose at birth followed by a series of three further OPV doses in polio-endemic countries [76]. More than half of newborns that received a monovalent-OPV had seroconverted 30 days after priming [77], showing this strategy to be effective. However, OPV is a live infectious vaccine that also contains RNA thereby ensuring its ability to activate both DAMPS and PAMPS, effectively acting as inbuilt adjuvants [78], and this likely explains its effectiveness in neonates.

As opposed to the few vaccines mentioned above, most vaccines are only administered after the neonatal phase has passed. Starting at 2 months of age, vaccines administered to infants include rotavirus vaccine (2 and 4 months), diphtheria, pertussis, tetanus (DTaP) (2, 4, 6, and 15–18 months), Hib conjugate (2, 4, 6, 12–15 months), pneumococcal conjugate (PCV; 2, 4, 6, 12–15 months), IPV (2, 4, 6–18 months), seasonal
influenza (6 months and older), measles, mumps, and rubella (MMR) (12 months), varicella (12 months), and hepatitis A (12–18 months) (reviewed in [70,79]). The major reason for this delay is two-fold; first, there is an age-dependent increase in seroconversion rates if vaccination is delayed and also this delay avoids much of the potential problem of maternal antibody interference [13,23,26].

Many attempts to immunize children at birth with other vaccines have been unsuccessful. For example, immunization at birth with pertussis vaccines resulted in a reduced response to pertussis boosters at up to 5 months of age, which was independent of maternal Abs [80]. Conversely, if immunization was delayed until 3 weeks of age the serological response to pertussis was significantly improved [81,82]. A study of rotavirus vaccine similarly found the response was less robust, the earlier in life the vaccine was given [83]. Questions are also raised of whether neonatal vaccination might induce persistent immune hypo-responsiveness, due to immune paralysis, tolerance or Ag interference [70,84,85]. For example, DTaP vaccine given at birth was associated with significantly reduced Ab responses to DTaP boosters through to 7 months of age [86].

In summary, two of the three vaccines given at birth are live organisms (BCG, rotavirus) that express multiple inbuilt PAMPs and in the act of infection also induce endogenous DAMPs, thereby explaining their effectiveness. The third example is a recombinant antigen (HBsAg) where the role of the birth dose of this vaccine is just to protect against immediate infection transmission at the time of birth, with subsequent immunity provided by additional immunizations starting at 2 months. The key question is whether specific adjuvants or adjuvant combinations could be used to replicate the effects of the live BCG and rotavirus vaccines and thereby improve neonatal vaccine responses.

6. Neonatal vaccines against influenza and RSV

ALRI are the most common cause of infant mortality worldwide, with influenza, RSV, parainfluenza, and human metapneumovirus being the most common causes of ALRI in children [9,87–90]. Vaccination is the primary strategy for prevention of influenza [91,92]. Currently licensed influenza vaccines include trivalent or quadrivalent inactivated vaccines (TIV/QIV) and intranasal live attenuated influenza vaccine (LAIV) [93]. Even though both TIV/QIV and LAIV are effective in preventing influenza and its associated complications in children 6 months and older, neither of them is indicated for neonates due to poor responses to inactivated vaccines and increased side effects from LAIV vaccines [94,95]. A single dose of TIV failed to induce seroconversion against H1N1 strains in infants less than 3–5 months of age and seroprotection was only seen in ~29% of infants even after a second dose, with a correlation between the age of first immunization and the rate of seroconversion [96]. This leaves neonates highly vulnerable to infection in the absence of an effective neonatal influenza vaccine.

No vaccine is licensed anywhere in the world for the prevention of RSV disease. The initial RSV vaccine tested in 1960s was a formalin-inactivated whole-virus vaccine formulated with alum adjuvant [97]. Although infants immunized with a 3-dose series administered between 2 and 7 months of age developed RSV-specific serum Ab responses, these were non-neutralizing, failed to protect against RSV infection and ultimately exacerbated infection outcomes (vaccine-enhanced disease) [98,99]. Major obstacles remain to successful development of a neonatal RSV vaccine. Although a high serum neutralizing Ab titer is able to prevent ALRI due to RSV in adults, it is more difficult to induce high Ab levels in neonates. Even if an adjuvant could induce high Ab responses in neonates, there is still the issue of vaccine-enhanced disease. Data from rodent models suggest that vaccine-enhanced disease is associated with priming of an excessive Th2 response, a factor exacerbated by the Th2 adjuvant, alum [100,101]. Although alternative adjuvants, most notably TLR agonists, have been suggested to overcome the problem of RSV vaccine-enhanced disease in animal models, even TLR agonists have a Th2 bias in young infants and ability to use this strategy to prevent vaccine-enhanced disease has yet to be confirmed in human infants.

7. Adjuvants for neonatal vaccines

Novel adjuvants may assist the development of effective neonatal vaccines with the current major focus being on TLR agonists. TLR2 and TLR5 ligands primarily enhance Ab production whereas TLR3, 7, 8 and 9 ligands promote a Th1 polarized response (reviewed in [21,102]). Monophosphoryl Lipid A (MPLA), a TLR4 ligand when combined with alum or QS21 enhances Ab response. However, while these TLR adjuvants have been demonstrated to be effective in older children and adults, there is still no guarantee that they will work in human neonates. Neonates exhibit reduced responsiveness of TLR and inflammasome pathways [46,103,104]. In particular, they have a defect in pro-caspase 1 cleavage that contributes to the low responses of human neonatal cells to adjuvants targeting the IL-1β/inflammasome pathway [103]. Endosomal TLRs such as TLR-3 or −7 may have better preserved activity in neonates [105–107] but in our experience are still not able to fully compensate for the reduced responses to influenza vaccine in neonatal mice (manuscript in preparation).

As depicted in Figure 2, addition of an adjuvant to neonatal vaccine formulations might help accelerate maturation of the neonatal immune system, thereby enhancing Ag presentation, increasing T and B cell co-stimulatory signals and overriding reduced neonatal vaccine responses. Adjuvants could potentially be used to enhance neonatal TFH T cell responses, increase the frequency and quality of GC and memory B cell responses and thereby enhance high-affinity broadly neutralizing Ab production in addition to enhancing cellular (Th1) immunity [108–110]. Unfortunately, there is a paucity of available data on the utility of adjuvants to enhance immune responses to vaccines in human neonates. While alum adjuvanted HBV vaccine is effective in infants and adults, it was not effective in preterm neonates [111–114].

Most neonatal data on novel adjuvants still comes from neonatal animal models, with uncertainty as to how well
this might reflect the situation in human neonates. The squalene oil emulsion adjuvant, MF59, failed to induce protective influenza antibody responses when used to immunize 7-day old mice vaccine, even when a second booster dose was administered [115]. By contrast, a lipidated TLR7/8 agonist was reported to enhance B cell responses to a polysaccharide pneumococcal vaccine when administered to rhesus macaques on the first day of life [109]. Overall, there is a paucity of data to demonstrate that traditional adjuvants used in adults, are effective in neonates.

8. Benefits of sugar-based adjuvants in neonatal vaccines

As noted previously, BCG is one of the few vaccines that are effective in newborns. BCG expresses glycolipids, glycopeptides and other sugar-based structures that are potent activators of the innate immune system. The success of BCG raises the question of whether sugar-based immune activators may be able to preferentially activate the neonatal immune system. Trehalose 6,6'-dibehenate (TDB) is a synthetic analog of mycobacterially-expressed trehalose-6,6-dimycolate (TDM) that targets the PAMP receptor, MINCLE (macrophage inducible Ca\(^{2+}\)-dependent lectin receptor). TDB was shown to activate human newborn DCs and enhanced Th1 polarizing cytokine production by DCs when given in combination with a TLR7/8-ligand [116]. TDB enhanced protection against influenza in immunized neonatal mice through the induction of Tfh cells and high-affinity plasma cells [110]. CAF01, a cationic adjuvant formulation consisting of TDB in dimethyl dioctadecyl ammonium (DDA) delivery vehicle successfully induced Th1/Th17 responses in murine neonates [117]. Curdlan, a water-insoluble linear beta-1,3-glucan produced by bacteria was also shown to enhance Th1 responses to a subunit TB vaccine [110] and an influenza vaccine in neonatal mice [118]. Zymosan, a glucose-based polysaccharide expressed by yeast that activates multiple PAMP receptors including TLR2 and the glucan receptor, induced comparable cytokine levels in cord blood and adult blood monocytes and DCs [119], raising the possibility it may also be an effective neonatal adjuvant.

The above data supports the hypothesis that sugar-based compounds may uniquely activate the neonatal adaptive immune system in a way that supports the induction of more adult-like memory responses. Although the exact mechanism for this favorable action is not known, TDB is known to activate MINCLE and Curdlan activates Dectin-1. MINCLE and Dectin-1 are both C-type lectin receptors. TDB and Curdlan have been shown in neonatal mice to enhance protection against influenza through the induction of TFH, GCs, and bone marrow high-affinity plasma cells [110]. This suggests that activation of C type lectin receptors by sugar-based compounds may specifically bypass blocks to other innate immune pathways in neonates and thereby boost neonatal vaccine responses.
9. Delta inulin (Advax) as a neonatal vaccine adjuvant

Delta inulin, a plant-based polysaccharide, is the basis of Advax adjuvant. Inulin is a fructan comprised of a linear chain of fructose units connected by β-(2–1) glycosidic bonds and capped at the reducing end by an α-D-(1–2)-glucopyranoside ring [120,121]. The inulin must be crystallized into microparticles known as delta inulin to become adjuvant active, with soluble inulin having no measurable immunological activity. Advax alone or in combination with TLR agonists has proved effective in enhancing humoral and cellular immunity in adult animals against a broad range of pathogens including influenza, Japanese encephalitis virus, West Nile virus, tuberculosis, anthrax, African horse sickness, HIV, lysteria and HBV, amongst others (reviewed in [121]). Advax adjuvant similarly afforded complete protection to murine pups vaccinated at 7 days of age with a single-dose of inactivated influenza vaccine whereas the influenza vaccine alone provided no protection [108]. The Advax-formulated vaccine induced significantly higher levels of serum influenza-specific Ab of both Th1 and Th2 isotypes plus a 3–4 fold increase in the frequency of influenza-specific IgM and IgG secreting cells in the spleen and bone marrow [108]. Pups immunized with Advax-formulated vaccine also had significantly higher influenza-specific T cell production of IFN-γ, IL-2, IL-4, and IL-10 together with a 3–10-fold higher frequency of influenza-specific T cells on ELISPOT secreting IFN-γ IL-2, IL-4 and IL-17 [108]. No adverse effects were observed in the Advax-immunized pups even although they received the same 1 mg dose of Advax used in adult mice. The ability of Advax adjuvant to enhance neonatal influenza vaccine protection so effectively raises many questions, including the nature of the mechanisms whereby it achieves this effect. Notably, in exactly the same neonatal influenza model we have shown that the TLR9 agonist, CpG2006, had no adjuvant activity and provided no protection to the 7-day old-immunized pups (manuscript in preparation). Neonatal protection with Advax-adjuvanted influenza vaccine was dependent on functional B cells as protection was not seen in immunized μMT neonates that were B cell deficient [108].

The exact mechanism(s) by which Advax enhances the immunogenicity of influenza vaccine in animal models and human clinical trials has yet to be determined. Delta inulin does not activate classical inflammatory innate immune receptors such as the TLRs, but instead works through another receptor or non-receptor mechanism to modulate the function of DCs [120,122] inducing chemotaxis and enhancing expansion of memory T and B cells. In murine TB studies, addition to Advax to a TLR9 agonist, CpG oligonucleotide (Advax-CpG), improved both the immunogenicity and protective efficacy of a novel TB vaccine candidate, CysVac2 [123]. Immunization with CysVac2 with Advax-CpG resulted in heightened release of the chemoattractants, CXCL1, CCL3, and TNF-α and rapid influx of monocytes and neutrophils to the site of vaccination, with pronounced early priming of CysVac2-specific CD4+ T cells.

Human subjects immunized with Advax-adjuvanted seasonal influenza vaccine had increased serum neutralizing antibody titers with an increased frequency of plasmablasts seen in their peripheral blood days 7 post vaccination [124]. These plasmablasts when sorted and sequenced exhibited a 2–3 fold higher rate of non-silent mutations in the B cell receptor (BCR) heavy chain complementarity-determining region (CDR3). This was associated with higher plasmablast expression of activation-induced cytidine deaminase (AICDA), the major enzyme controlling BCR affinity maturation, providing a mechanism to explain the enhanced neutralizing antibody responses seen in subjects receiving Advax adjuvant.

While studies are ongoing in animal models to determine how Advax adjuvant enhances humoral immune responses, preliminary results suggest this is dependent on enhanced activation of CD4+ T cells. We thereby hypothesize that Advax increases the frequency of TFH cells which then act to enhance antigen-specific B cell activation, BCR affinity maturation, IgG switching and production of high avidity Ab. Whether this action of Advax on enhanced activation of CD4+ T cells might be mediated by interaction with one or more C type lectin receptors expressed on APC is not known. However, Advax’s non-inflammatory effect on human PBMC suggests it is not acting through one of the pro-inflammatory types of C type lectin receptors such as MINCLE, Dectin-1 or-2 or DC-SIGN.

10. Use of combination adjuvants in neonatal vaccines

Compared with the effects in adult blood, LPS (TLR4), Pam3CSK4 (TLR2), flagellin (TLR5) or Poly I:C (TLR3) stimulated weaker inflammatory cytokine production in cord blood monocytes. A Haemophilus influenza B vaccine, adjuvanted with the outer membrane protein (OMP, Porin B (PorB) from Neisseria meningitidis), a TLR2 agonist, induced minimal Ab in neonates and was only protective when the first dose was given after 2 months of age. This suggests that TLR signals alone may be relatively inefficient in stimulating neonatal vaccine responses. Furthermore, TLR-7/8 and TLR-9 adjuvants, which induce Th1 responses in adults, paradoxically induce Th2 responses in neonates. Notably, Advax can be combined with traditional innate immune activators, such as TLR and NOD2 agonists, to further enhance its adjuvant activity. Notably, when co-formulated with CpG oligonucleotide, Advax not only enhanced the immunogenicity of a SARS coronavirus vaccine but also prevented vaccine-associated eosinophilic lung pathology, a problem exacerbated by formulation of SARS vaccine with an alum adjuvant [125]. Hence, it will be interesting to see how the co-formulation of Advax and CpG oligonucleotide performs in a neonatal setting.

11. Conclusion

There is a major need for vaccines that can be used to protect young infants. Emerging data suggests that particular immune pathways, including the C type lectin receptors, that respond to sugar structures may be particularly effective at activating the
infant immune system. This may help explain the beneficial effects on neonatal vaccine responses of sugar-based compounds including delta inulin (Advax), curdlan, and TDB. Hence, additional research into these alternative immune pathways induced by sugar-based compounds might help elucidate additional compounds able to enhance neonatal vaccine responses. This is a promising area of investigation for development of neonatal vaccines against pathogens that cause significant infant morbidity and mortality including influenza and RSV.

12. Expert opinion

The millions of deaths in neonates and infants from infectious disease annually, emphasize the need to develop more effective strategies for early-life immunization. The success of BCG and rotavirus vaccines given at birth is proof-of-concept that effective and safe neonatal immunization is feasible [126,127]. A framework to allow discovery of neonatal age-specific adjuvants is needed. Comparing responses of various immune-stimulators in cord and adult blood may not translate to complex adjuvant effects in vivo [128–131]. Ultimately, answers will only come from human neonatal studies of vaccines containing novel adjuvants. To assist progress, there is a need to define and validate specific neonatal biomarkers of vaccine and adjuvant safety and efficacy. The beneficial effects in neonatal animal models of sugar-based adjuvants such as delta inulin, curdlan, and TDB on neonatal vaccine responses highlight the ability to identify compounds able to enhance neonatal vaccine responses. To understand the specific benefits of these compounds, more research is needed into the differences in immune signaling pathways between newborns and adults. Systems biological analysis of the host response to vaccination has provided new insights into the adult immune response to vaccination [132,133]. Systems biology approaches employ high-throughput molecular and cellular measurements called ‘OMICS’ analysis [134]. For example, transcriptomic analyses showed early gene signatures following vaccination were predictive of subsequent measures of immunogenicity for seasonal influenza [135]. These high-dimensional methodologies could be applied to characterization of neonatal vaccine-induced molecular signatures that correspond to protection [79,136,137]. The importance of formulation to vaccine effectiveness is often overlooked, and hence there is also a need for research into development of new and improved formulations and stable delivery systems to improve neonatal vaccine immunogenicity. New knowledge will help in the rational design of neonatal vaccines and adjuvants, reduce empiricism and lessen the risk of failed vaccine candidates, thereby expediting the development of effective neonatal vaccines.

Funding

This work was supported in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272200800039C, and Collaborative Research Contact No. U01AI061142 (to NP), and Clinical and translational Science Institute award TL1 TR001858 (to Katherine ME). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

Declaration of interest

I Sakala is an employee of Vaxine Pty Ltd, which developed the Advax adjuvant, and is an academic affiliate of the Flinders University. N Petrovsky is the founder and Research Director of Vaxine Pty Ltd, and is an academic affiliate of the Flinders University. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

References

Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.

1. WHO, PMNCH. Newborn death and illness. Partnership for Maternal, Newborn & Child Health, News and Media Centre Fact sheets. http://www.who.int/pmnch/media/press_materials/fs/fs_newborndealth_illness/en/; (2011).
2. Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385 (9966):430–440.
3. WHO. Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec. 2012;87(47):461–476.
4. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med. 2006;355(1):31–40.
5. Poehling KA, Edwards KM, Griffin MR, et al. The burden of influenza in young children, 2004–2009. Pediatrics. 2013;131(2):207–216.
6. Coffin SE, Zaoutis TE, Rosenquist ABW, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics. 2007;119(4):740–748.
7. Ampofo K, Gesteland PH, Bender J, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics. 2006;118(6):2409–2417.
8. Glezen WP, Taber LH, Frank AL, et al. Influenza virus infections in infants. Pediatr Infect Dis J. 1997;16(11):1065–1068.
9. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917–1930.
10. A review on the burden of influenza-associated lower respiratory tract infection in children <5 years old worldwide.
11. Dudas RA, Carron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev. 1998;11(3):430–439.
12. Morein B, Abusugra I, Blomqvist G. Immunity in neonates. Vet Immunol Immunopathol. 2002;87(3–4):207–213.
13. Siegrist CA. Neonatal and early life vaccination. Vaccine. 2001;19(25–26):3331–3346.
14. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature. 1953;172(4379):603–606.
15. Kollmann TR, Kampmann B, Mazmanian SK, et al. Protecting the newborn and young infant from infectious diseases: lessons from immune ontogeny. Immunity. 2017;46(3):350–363.
This review gives a comprehensive overview of the current understanding of the neonatal immune system. The authors discuss that differences in susceptibility to infection result not out of a state of immaturity, but rather reflect adaptation to the particular demands placed on the immune system in early life, which they contributed substantially to elucidate.

16. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Expert Rev Clin Immunol. 2014;10(9):1171–1184.

**Review on neonatal immunity.**

17. Riese I, Schulze K, Ebensen T, et al. Vaccine adjuvants: key tools for innovative vaccine design. Curr Top Med Chem. 2013;13(20):2562–2580.

18. O’Hagan DT, Fox CB. New generation adjuvants—from empiricism to rational design. Vaccine. 2015;33(Suppl 2):S14–20.

19. Savekoul HF, Ferro VA, Strioga MM, et al. Choice and design of adjuvants for parenteral and mucosal vaccines. Vaccines (Basel). 2015;3(1):148–171.

20. Wilson-Welder JH, Torres MP, Kipper MJ, et al. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci. 2009;98(4):1278–1316.

21. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunol. 2010;33(4):492–503.

22. Morein B, Blomqvist G, Hu K. Immune responsiveness in the neonatal period. J Comp Pathol. 2007;137(Suppl 1):S27–31.

23. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol. 2009;9(3):185–194.

24. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol. 2007;7(5):379–390.

25. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol. 2004;4(7):533–564.

26. Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol. 2014;5:446.

27. Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine. 2003;21(24):3406–3412.

28. Siegrist CA. The challenges of vaccine responses in early life: selected examples. J Comp Pathol. 2007;137(Suppl 1):S4–9.

29. Michaelsson J, Mold JE, McCune JM, et al. Regulation of T cell responses in the developing human fetus. J Immunol. 2006;176(10):5741–5748.

30. Fernandez MA, Putter FK, Wang YM, et al. T regulatory cells contribute to the attenuated primary CD8+ and CD4+ T cell responses to herpes simplex virus type 2 in neonatal mice. J Immunol. 2008;180(3):1556–1564.

31. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015;16:343.

32. Sun CM, Deriaud E, Leclerc C, et al. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal dendritic cells. J Exp Med. 2005;222(4):467–477.

33. Sun CM, Deriaud E, Leclerc C, et al. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal dendritic cells. J Exp Med. 2005;222(4):467–477.

34. Krumbiegel D, Zepp F, Meyer CU. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells. Hum Immunol. 2007;68(10):813–822.

35. Allen CD, Cyster JG. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin Immunol. 2008;20(1):14–25.

36. MacLennan IC. Germinal centers. Annu Rev Immunol. 1994;12:117–139.

37. Wang X, Cho B, Suzuki K, et al. Follicular dendritic cells help establish follicle identity and promote B cell retention in germinal centers. J Exp Med. 2011;208(12):2497–2510.

38. Plotkin SA. Complex correlates of protection after vaccination. Clin Infect Dis. 2013;56(10):1458–1465.

39. Zemlin M, Hoersch G, Zemlin C, et al. The postnatal maturation of the immunoglobulin heavy chain IgG repertoire in human preterm neonates is slower than in term neonates. J Immunol. 2007;178(2):1180–1188.

40. Glezen WP. Effect of maternal antibodies on the infant immune response. Vaccine. 2003;21(24):3389–3392.

41. Burt TD. Fetal regulatory T cells and peripheral immune tolerance in utero: implications for development and disease. Am J Reprod Immunol. 2013;69(4):346–358.

42. Moore AC, Gallimore A, Draper SJ, et al. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. J Immunol. 2005;175(11):7264–7273.

43. Ho P, Wei X, Seal GT. Regulatory T cells induced by Mycobacterium chelonae sensitization influence murine responses to bacille Calmette-Guérin. J Leukoc Biol. 2010;88(6):1073–1080.

44. Flanagan KL, Halliday A, Burl S, et al. The effect of placental malaria infection on cord blood and maternal immunoregulatory responses at birth. Eur J Immunol. 2010;40(4):1062–1072.

45. Walther B, Miles DJ, Waight P, et al. Placental malaria is associated with attenuated CD4 T-cell responses to tuberculin PPD 12 months after BCG vaccination. BMC Infect Dis. 2012;12(16).

46. Kollmann TR, Levy O, Montgomery RR, et al. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunol. 2012;37(5):771–783.

47. CDC. Flu-related hospitalizations and deaths in the United States from April 2009 – January 30, 2010. 2010. Available from 2019 Feb 7 https://www.cdc.gov/h1n1flu/hosp_deaths_ahdra.htm

48. Zaghoubi H, Hoeman CM, Adkins B. Neonatal immunity: faulty T-helper and the shortcomings of dendritic cells. Trends Immunol. 2009;30(12):585–591.

49. Marchant A, Goetghébeur T, Ota MO, et al. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J Immunol. 1999;163(4):2249–2255.

50. Ravn P, Boesen H, Pedersen BK, et al. Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Guerin. J Immunol. 1997;158(4):1949–1955.

51. Mascart F, Verscheure V, Malrroot A, et al. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol. 2003;170(3):1504–1509.

52. Huygens A, Lecomte S, Tackoen M, et al. Functional exhaustion limits CD4+ and CD8+ T-cell responses to congenital cytomegalovirus infection. J Infect Dis. 2015;212(3):484–494.

53. Snapper C, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science. 1987;236(4804):944–947.

54. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173.

55. Harada Y, Tanaka S, Motomura Y, et al. The 3’ enhancer CNS2 is a critical regulator of interleukin-4-mediated humoral immunity in follicular helper T cells. Immunity. 2012;36(2):188–200.

56. Luthje K, Kallies A, Shimohakamada Y, et al. The development and fate of follicular helper T cells defined by an IL-21 reporter mouse. Nat Immunol. 2012;13(5):491–498.

57. Vijayanan P, Seumois G, Simpson LJ, et al. Interleukin-4 production by follicular helper T cells requires the conserved IL4 enhancer hypersensitivity site IV. Immunity. 2012;36(2):175–187.

58. Yusuif I, Kageyama R, Montecilli L, et al. Germinal center T follicular helper cell IL-4 production is dependent on signaling lymphocytic activation molecule receptor (CD150). J Immunol. 2010;185(1):190–202.

59. Dullaers M, Li D, Xue Y, et al. A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secretion plasmablasts. Immunity. 2009;30(1):120–129.

60. Tsuji M, Komatsu N, Kawamoto S, et al. Preferential generation of CD8+ T cells in gut Peyer’s patches. Science. 2009;323(5920):1488–1492.

61. Heshima K, Kawasaki Y, Hanamoto H, et al. CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J Immunol. 2004;173(6):3668–3675.
This study identified T follicular helper cells as a leverage point that limit/may improve humoral responses to vaccines in early life.

62. Sarzotti M, Robbins DS, Hoffman PM. Induction of protective CTL responses in newborn mice by a murine retrovirus. Science. 1996;271(5256):1726–1728.

63. Debock I, Jaworski K, Chadalouli H, et al. Neonatal follicular Th cell responses are impaired and modulated by IL-4. J Immunol. 2013;191(3):1231–1239.

64. Mastelic B, Kamath AT, Fontannaz P, et al. Environmental and T cell-intrinsic factors limit the expansion of neonatal follicular T helper cells but may be circumvented by specific adjuvants. J Immunol. 2012;189(12):5764–5772.

- This study identified T follicular helper cells as a leverage point that limit/may improve humoral responses to vaccines in early life.

65. Sarzotti M, Robbins DS, Hoffman PM. Induction of protective CTL responses in newborn mice by a murine retrovirus. Science. 1996;271(5256):1726–1728.

66. Fadel SA, Ozaki DA, Sarzotti M. Enhanced type 1 immunity after neonatal vaccination. Infect Immun. 2012;80(11):4456–4464.

67. Hunt DW, Huppertz HJ, Jiang HJ, et al. Studies of human cord blood dendritic cells: evidence for functional immaturity. Blood. 1994;84(12):4333–4343.

68. Heldwein KA, Liang MD, Andresen TK, et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J Leukoc Biol. 2003;74(2):277–286.

69. Pompei L, Jang S, Zamlynn B, et al. Disparity in IL-12 release in dendritic cells and macrophages in response to Mycobacterium tuberculosis is due to use of distinct TLRs. J Immunol. 2007;178(8):5192–5199.

70. Demirjian A, Levy O. Safety and efficacy of neonatal vaccination. Eur J Immunol. 2009;39(1):36–46.

71. Price DN, Kusewitt DF, Lino CA, et al. Oral tolerance to environmental mycobacteria interferes with intradermal, but not pulmonary, immunization against tuberculosis. PLoS Pathog. 2016;12(5):e1005614.

72. Wong VC, Ip HM, Reesink HW, et al. Prevention of the HBSAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet. 1984;1(8383):921–926.

73. Xu Z-Y, Liu C-B, Francis DP, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics. 1995;76(5):713–718.

74. Gerlich WH. Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol. 2015;204(1):39–55.

75. Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J. 1993;12(5):438–445.

76. WHO. In International travel and health > Vaccines > Poliomyelitis (Polio). Available from 2019 February 4th. https://www.who.int/ith/vaccines/polio/en/

77. el-Sayed N, el-Gamal Y, Abbassy AA, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med. 2008;359(16):1655–1665.

78. Phiblin VJ, Levy O. Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities. Biochem Soc Trans. 2007;35(6):1485–1491.

79. Whitaker E, Goldblatt D, McIntyre P, et al. Neonatal immunization: rationale, current state, and future prospects. Front Immunol. 2018 Apr 4;9:532. doi: 10.3389/fimmu.2018.00532. eCollection 2018.

80. Provenzano RW, Wetterlow LH, Sullivan CL. Immunization and antibody response in the newborn infant. I. Pertussis inoculation within twenty-four hours of birth. N Engl J Med. 1965;273(18):959–965.

81. Chot C. Pertussis: acellular, whole-cell, new vaccines, what to choose? Expert Rev Vaccines. 2016;15(6):671–673.

82. Chot C, Miellarek N. New pertussis vaccination approaches: en route to protect newborns? FEMS Immunol Med Microbiol. 2012;66(2):121–133.

83. Saleh E, Eichner B, Clark DW, et al. Open-label pilot study to compare the safety and immunogenicity of pentavalent rotavirus vaccine (RV5) administered on an early alternative dosing schedule with those of RV5 administered on the recommended standard schedule. J Pediatr Infect Dis Soc. 2017;7(1):82–85.

84. Siegert CA. Blame vaccine interference, not neonatal immunization, for suboptimal responses after neonatal diphtheria, tetanus, and acellular pertussis immunization. J Pediatr. 2008;153(3):305–307.

85. Wood N, Siegert CA. Neonatal immunization: where do we stand? Curr Opin Infect Dis. 2011;24(3):190–195.

86. Halasa NB, O’Shea A, Shi JR, et al. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr. 2008;153(3):327–332.

87. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–1555.

88. Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. (2016). May 2016. Available from https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf.

89. Meissner HC, Rennels MB. Unpredictable patterns of viral respiratory disease in children. Pediatrics. 2004;113(6):1814–1816.

90. Brodzinski H, Ruddy RM. Review of new and newly discovered respiratory tract viruses in children. Pediatr Emerg Care. 2009;25(5):352–360; quiz 361–353.

91. Nichol KL, Treanor J. Vaccines for seasonal and pandemic influenza. J Infect Dis. 2006;194(Suppl 2):S111–S118.

92. Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol. 2009;333:43–82.

93. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP). 2010. MMWR Recomm Rep. 2010;59(RR–8):1–62.

94. Vesikari T. Emerging data on the safety and efficacy of influenza vaccines in children. Pediatr Infect Dis J. 2008;27(11 Suppl):S159–S161.

95. Vesikari T, Karvonen A, Smith HM, et al. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age. Pediatrics. 2008;121(3):568–573.

96. Groothuis JR, Levin MJ, Rabalais GP, et al. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. Pediatrics. 1991;87(6):823–828.

97. Chin J, Magoffin RL, Sheetter LA, et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89(4):449–463.

98. Murphy BR, Prince GA, Walsh EE, et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol. 1986;24(2):197–202.

99. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–434.

100. Graham BS, Henderson GS, Tang YW, et al. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol. 1993;151(4):2032–2040.

101. Knudson CJ, Hartwig SM, Meyerholz DK, et al. RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog. 2015;11(3):e1004757.

102. Netea MG, Van der Meer JW, Sutmuller RP, et al. From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob Agents Chemother. 2005;49(10):3991–3996.

103. Sharma AA, Jen R, Kan B, et al. Impaired NLRP3 inflammasome activity during fetal development regulates IL-1β production in human monocytes. Eur J Immunol. 2015;45(1):238–249.
This study was the first evidence of delta inulin as a potent neonatal vaccine adjuvant. Advac adjuvant overcame neonatal immune hyporesponsiveness to establish protection of murine neonates vaccinated against lethal influenza following a single-dose of inactivated influenza vaccine (H1N1) administered at seven days of age.

This study identifies a new cellular and molecular pathway functional in cord blood cells which could be targeted to elicit stronger neonatal Th1 responses.

In this study, the MINCLE agonist, TDB, and the Dectin-1 agonists, curdlan and CDP10, were shown in a neonatal mouse model to enhance Ab responses and protection against influenza challenge through the induction of ThF, GCS, and bone marrow high-affinity plasma cells.

In this study, the Mincle agonist, TDB, and the Dectin-1 agonist, Curdlan, both sugar compounds that activate C type lectin receptors, were shown in a neonatal mouse model to enhance Ab responses and protection against influenza vaccine at birth. JCI Insight. 2017;2(6):e91020.

This study describes the discovery and development of Advax adjuvant and research into its unique mechanism of action.

This review describes the discovery and development of Advax adjuvant as well as its unique mechanism of action.